Biologically Active Small Molecules

D-erythro-Sphinganine is a precursor of ceramide and sphingosine as well as a substrate of sphingosine kinases, which generate sphinganine-1-phosphate. Sphinganine levels increase significantly in response to certain mycotoxins, including

A naturally-occurring but rare form of sphingosine.

A naturally-occurring but rare form of sphingosine.

A naturally-occurring but rare form of sphingosine.

A naturally-occurring but rare form of sphingosine.

A naturally-occurring but uncommon form of sphingosine, accounting for approximately 13% of the sphingosine in human skin can be phosphorylated by sphingosine kinases to produce C-17 sphingosine-1-phosphate.

A naturally-occurring but uncommon form of sphingosine, accounting for approximately 13% of the sphingosine in human skin can be phosphorylated by sphingosine kinases to produce C-17 sphingosine-1-phosphate.

A naturally-occurring but uncommon form of sphingosine, accounting for approximately 13% of the sphingosine in human skin can be phosphorylated by sphingosine kinases to produce C-17 sphingosine-1-phosphate.

A naturally-occurring but uncommon form of sphingosine, accounting for approximately 13% of the sphingosine in human skin can be phosphorylated by sphingosine kinases to produce C-17 sphingosine-1-phosphate.

D-erythro-Sphingosine is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatic acid phosphohydrolase, whereas it activates PLD and DAG kinase.

D-erythro-Sphingosine is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatic acid phosphohydrolase, whereas it activates PLD and DAG kinase.

D-erythro-Sphingosine is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatic acid phosphohydrolase, whereas it activates PLD and DAG kinase.